NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy

Egyptian Liver Journal

Table 2 Virological response in the study group

Item	F3, F4	F0–F2	Total
Response:
• Patients who achieved SVR12	92.9% (26/28)	100% (31/31)	57 (96.6%)
• Patients who did not achieve SVR12	7.1% (2/28)	0 (0%)	2 (3.4%)
p value	0.001*	NA	0.001*

Total number = 59 patients
NA not applicable, SVR12 sustained virological response with HCV RNA negative at 12 weeks after the end of therapy
* Statistically significant